Strides Of India Said Holding Attractive Sale Opportunity With Its Agila Unit
This article was originally published in PharmAsia News
India's Strides Arcolab reportedly is in a good position to gain a good price by selling its Agila Specialties cancer and antibiotics unit, according to sources.
You may also be interested in...
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.